Přístupnostní navigace
E-application
Search Search Close
Publication detail
MASARYK, L. WEISER DROZDKOVÁ, D. SLOCZYNSKA, K. MONCOL, J. MILDE, D. KRIKAVOVA, R. POPIOL, J. PEKALA, E. ONDRUŠKOVÁ, K. NEMEC, I. SMEŠNÝ, K. ŠTARHA, P.
Original Title
Anti-myeloma pro-apoptotic Pt(II) diiodido complexes
Type
journal article in Web of Science
Language
English
Original Abstract
Platinum-based agents unwaveringly hold their prominent position in cancer treatment. Current research emphasizes finding novel complexes for hard-to-treat cancers with minimum side effects, capable of overcoming resistance. This work presents easy-to-prepare diiodidoplatinum(II) complexes cis-[PtI2(L-n)(2)] (1-7) with imidazole derivatives (L-n), which were considerably effective against multiple myeloma cell lines U266B1 and KMS12-PE. The leading compound 6 (at 3 mu M concentration) extraordinarily reduced viability of U266B1 and KMS12-PE myeloma cells to 3.0% and 1.1%, respectively, and exceeded the conventional platinum-based anticancer drug cisplatin (93.1% and 88.3%, respectively) that is used clinically for the combination therapy of multiple myeloma. Complex 6 was significantly more effective in inducing apoptosis in KMS12-PE cells without interleukin-6 (IL-6) expression than in U266B1 cells with IL-6 expression. Complex 6 also induced apoptosis in co-culture of KMS12-PE with non-cancerous stromal fibroblasts (HS-5), and displayed markedly lower activity in the HS-5 stromal fibroblast cells than in myeloma cells, pointing out its pharmocologically prospective selectivity towards the cancer cells over the normal ones. No caspase 3/7 activity was detected in apoptotic KMS12-PE cells treated by complex 6 indicating a different mechanism of apoptosis action from cisplatin. This work demonstrates that simple non-classical platinum(II) complexes represent a new perspective for a monotherapy of hard-to-treat multiple myeloma.
Keywords
BONE-MARROW MICROENVIRONMENT; VITRO ANTITUMOR-ACTIVITY; DNA-BINDING; PLATINUM(II) COMPLEXES; MULTIPLE-MYELOMA; CYTOTOXIC ACTIVITIES; ANTICANCER ACTIVITY; L-METHIONINE; CELL-LINE; CISPLATIN
Authors
MASARYK, L.; WEISER DROZDKOVÁ, D.; SLOCZYNSKA, K.; MONCOL, J.; MILDE, D.; KRIKAVOVA, R.; POPIOL, J.; PEKALA, E.; ONDRUŠKOVÁ, K.; NEMEC, I.; SMEŠNÝ, K.; ŠTARHA, P.
Released
31. 5. 2023
Publisher
Royal Society of Chemistry
Location
CAMBRIDGE
ISBN
2052-1553
Periodical
Inorganic Chemistry Frontiers
Year of study
10
Number
11
State
United Kingdom of Great Britain and Northern Ireland
Pages from
3307
Pages to
3318
Pages count
12
URL
https://pubs.rsc.org/en/content/articlelanding/2023/QI/D3QI00327B
Full text in the Digital Library
http://hdl.handle.net/11012/244723
BibTex
@article{BUT184251, author="Lukáš {Masaryk} and Denisa {Weiser Drozdková} and Karolina {Sloczynska} and Ján {Moncol} and David {Milde} and Radka {Krikavova} and Justyna {Popiol} and Elzbieta {Pekala} and Katarína {Ondrušková} and Ivan {Nemec} and Kateřina {Smešný} and Pavel {Štarha}", title="Anti-myeloma pro-apoptotic Pt(II) diiodido complexes", journal="Inorganic Chemistry Frontiers", year="2023", volume="10", number="11", pages="3307--3318", doi="10.1039/d3qi00327b", issn="2052-1553", url="https://pubs.rsc.org/en/content/articlelanding/2023/QI/D3QI00327B" }